These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34277465)

  • 21. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of new vaccines and diagnostic reagents against tuberculosis.
    Mustafa AS
    Mol Immunol; 2002 Sep; 39(1-2):113-9. PubMed ID: 12213334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
    Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
    Front Immunol; 2020; 11():680. PubMed ID: 32411131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tuberculosis vaccines: hopes and hurdles.
    Ahsan MJ; Garg SK; Vashistha B; Sharma P
    Infect Disord Drug Targets; 2013 Oct; 13(5):318-21. PubMed ID: 24304353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis.
    Mwaba P; McNerney R; Grobusch MP; O'Grady J; Bates M; Kapata N; Maeurer M; Zumla A
    Trop Med Int Health; 2011 Jul; 16(7):819-27. PubMed ID: 21489070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
    Coppola M; Ottenhoff TH
    Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
    de Wet TJ; Warner DF; Mizrahi V
    Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recently disclosed chemical entities as potential candidates for management of tuberculosis.
    Stec J; Abourashed EA
    Pharm Pat Anal; 2015; 4(4):317-47. PubMed ID: 26174569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.
    Chin KL; Anis FZ; Sarmiento ME; Norazmi MN; Acosta A
    J Immunol Res; 2017; 2017():5212910. PubMed ID: 28713838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycobacteria-derived biomarkers for tuberculosis diagnosis.
    Druszczynska M; Wawrocki S; Szewczyk R; Rudnicka W
    Indian J Med Res; 2017 Dec; 146(6):700-707. PubMed ID: 29664027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Selecting and affinity analysis of DNA aptamers to MPT64 protein from Mycobacterium tuberculosis].
    Qin LH; Ma ZZ; Zheng RJ; Liu ZH; Lu JM; Hu ZY
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Jun; 31(6):453-8. PubMed ID: 19031807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines.
    Olsen A; Chen Y; Ji Q; Zhu G; De Silva AD; Vilchèze C; Weisbrod T; Li W; Xu J; Larsen M; Zhang J; Porcelli SA; Jacobs WR; Chan J
    mBio; 2016 May; 7(3):. PubMed ID: 27247233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evolution of IGRA researches].
    Ariga H; Harada N
    Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging therapeutic targets in tuberculosis: post-genomic era.
    Khasnobis S; Escuyer VE; Chatterjee D
    Expert Opin Ther Targets; 2002 Feb; 6(1):21-40. PubMed ID: 11901479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for developing tuberculosis vaccines: emerging approaches.
    Mollica A; Stefanucci A; Costante R
    Curr Drug Targets; 2013 Aug; 14(9):938-51. PubMed ID: 23469877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural and Functional Characterization of Rv0792c from Mycobacterium tuberculosis: Identifying Small Molecule Inhibitor against HutC Protein.
    Chauhan NK; Anand A; Sharma A; Dhiman K; Gosain TP; Singh P; Singh P; Khan E; Chattopadhyay G; Kumar A; Sharma D; Ashish ; Sharma TK; Singh R
    Microbiol Spectr; 2023 Feb; 11(1):e0197322. PubMed ID: 36507689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.